Advertisements – Advertising at The News And Times – advertising-newsandtimes.com | WE CONNECT!

Audio | Video | Top News | On Twitter | Security | FBI | Capitol Riot | JOSSICA | Trump | Russia | Putin | Russia – Ukraine War | Covid-19 | Brooklyn NY | Puerto Rico | World 

My News Links

July 1, 2022 1:15 am

The News And Times | Featured Posts | All Articles | Current News | Selected Articles | Shared Links | Opinions | In My Opinion | Sites | Blogs | Links | Twitter | Facebook

Categories
Current News

AstraZeneca and Ionis drug for rare disease achieves positive trial data

Advertisements - Advertising at The News And Times - advertising-newsandtimes.com | WE CONNECT!
Spread the news

Listen to this article
2022-06-21T07:47:40Z

The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo

An interim analysis of AstraZeneca (AZN.L) and partner Ionis Pharmaceuticals’ (IONS.O) eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday.

Advertisements - Advertising at The News And Times - advertising-newsandtimes.com | WE CONNECT!

Based on the results, the companies plan to file an application to market the therapy in the United States later this year in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).


Spread the news
Advertisements - Advertising at The News And Times - advertising-newsandtimes.com | WE CONNECT!
WP Radio
WP Radio
OFFLINE LIVE